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Abstract
Context: Zidovudine (AZT) is employed against AIDS and hepatitis; its use is limited by active
efflux transporters (AETs) that induce multidrug resistance for intracellular therapies and
hamper AZT to reach the brain. Ursodeoxycholic acid (UDCA) conjugation with AZT (prodrug
UDCA–AZT) allows to elude the AET systems.
Objective: To investigate the effect of the Pluronic F68 coating on the loading, release and
stability of poly(D,L lactide-co-glicolide) nanoparticles (NPs) embedded with UDCA–AZT.
Materials and methods: The mean diameter of the NP prepared by nanoprecipitation or
emulsion/solvent evaporation methods was determined using both photon correlation
spectroscopy and sedimentation field–flow fractionation; particle morphology was detected
by scanning electron microscope. The stability of the free and encapsulated UDCA–AZT was
evaluated in rat liver homogenates by high-performance liquid chromatography analysis.
Results and discussion: The mean diameter of the NPs was found to be 600 nm with a relatively
high polydispersity. The NPs obtained by emulsion/solvent evaporation were not able to
control the prodrug release, differently from NPs obtained by nanoprecipitation. The presence
of the Pluronic coating did not substantially modify the kinetics of the drug release, or the
extent of the burst effect that were instead only influenced by the preparation parameters.
UDCA–AZT incorporated in the NPs was more stable in the rat liver homogenates than the free
prodrug and no influence of the Pluronic coating was observed.
Conclusions: Considering the different potential applications of nanoparticles coated and
uncoated with Pluronic (brain and macrophage targeting, respectively), both of these
nanoparticle systems could be useful in the therapies against HIV.
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Introduction
Poly(D,L-lactide-co-glicolide) (PLGA) belongs to a family of
biodegradable polymers approved by US FDA for the use of
drug delivery (Makadia & Siegel, 2011) and widely used to
prepare micro- and nanoparticles. PLGA is biocompatible and
it is eliminated from the body through natural pathways, being
degraded to the lactic and glycolic acids (Jalil, 1990;
Johansen et al. 2000; Bala et al., 2004). In the field of
biomedical applications, the submicron size of the nanopar-
ticles (NPs) can allow their administration by a variety of
routes, such as intravenous, oral, nasal, ocular and transder-
mal (Chen et al., 2012; Danhier et al., 2012; Tomoda et al.,
2012). However, NPs can have some limitations due to their
small size and large surface area that can limit drug loading
and cause relative high burst release (Leo et al., 2006b;
Nafee et al., 2009). Indeed, NP size greatly affect drug release
rate. Generally, smaller NP size leads to a shorter average
diffusion path of the matrix-entrapped drug molecules
(Chorny et al., 2002) and can lead to particle–particle
aggregation, making physical handling of NP difficult in
liquid and dry forms (Contado et al., 2013). On the other
hand, the increase in the particle size seems to be associated
mainly with extended porosity of the polymeric matrix owing
to the enhancement of the drug loading. This effect
overcompensates the effect of the increasing diffusion path-
ways with increasing NP radius, resulting in increased drug
release with increasing device dimension (Siepmann et al.,
2004). Encapsulation studies in PLGA nanoparticulate sys-
tems are therefore of primary importance, in particular for
those drugs whose therapeutic effect and site-specific target-
ing needs are strictly related.
In this article we report an encapsulation study in PLGA
NP of a prodrug of zidovudine (AZT) obtained by conjugation
with ursodeoxycholic acid (UDCA). AZT is currently
employed in therapeutic protocols that use multiple drug
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combinations against HIV (De Clerk, 2009) but, unfortu-
nately, it is substrate of active efflux transport (AET) systems
that cause its efflux in the bloodstream from the membranes
inducing, therefore, multidrug resistance (MDR) for intracel-
lular therapies (Liang, 1987; Vyas et al., 2006) and the
inability of the drug to reach efficacious concentrations
in the CNS (Wong et al., 1993; Takasawa et al., 1997;
Pardridge, 2003).
We have recently evidenced that the ester conjugation of
AZT with UDCA allows obtaining a prodrug (UDCA–AZT;
Figure 1) that is able to elude the AET systems (Dalpiaz et al.,
2012). This prodrug appears, therefore, an interesting sub-
strate for encapsulation studies in PLGA nanoparticulate
systems potentially able to induce its delivery in specific sites
of the body. Indeed, loaded UDCA–AZT NP may contribute
to increase the AZT concentration in its therapeutic sites,
where the delivered prodrug should not be effluxed by the
AET systems.
In this article, we propose the formulation of UDCA–AZT-
loaded NP by nanoprecipitation or by emulsion–solvent
evaporation methods in presence of Pluronic F-68, a nonionic
bifunctional triblock copolymer surfactant used primarily in
pharmaceutical and cosmetic formulations as emulsifier
(HLB¼ 29) under the trade name of Poloxamer 188, which
has recently attracted a considerable interest as vehicle for
diagnostic and therapeutic agents (Batrakov & Kabanov,
2008). Taking into account the potential targets of the prodrug
UDCA–AZT, the NPs have been produced and characterized
in both unpurified and purified forms. The unpurified form
has been chosen taking into account that PLGA NP coated
with Pluronic F-68 can induce long circulating proprieties and
drug delivery in the brain (Gelperin et al., 2010). On the other
hand, purified NP may be useful for the prodrug targeting in
another activity site of AZT, i.e. macrophages (Owens III &
Peppas, 2006), which when infected by HIV produces and
harbors the virus for a long period (Carter & Ehrlich, 2008).
The size of the purified and unpurified NP has been
evaluate by photon correlation spectroscopy (PCS) studies
supported by sedimentation field flow fractionation (SdFFF)
technique, whose employment appeared of great utility to
identify the aggregation degree of the nanoparticulate systems.
NPs were then characterized by evaluating their prodrug
loading, their morphology and size and their ability to control
the UDCA–AZT release. Finally, in the aim to verify the
ability of the NP to stabilize the prodrug in physiological
environments, we have considered that rat liver homogenates
induce high instability of UDCA–AZT, causing its hydrolysis
in few minutes (Dalpiaz et al., 2012); we have therefore
employed rat liver homogenates to compare the hydrolysis rate
of the prodrug in the free and encapsulated forms.
Materials and methods
Materials
The prodrug UDCA–AZT (solubility in water¼ 0.0030
 0.0001 mg/mL 4.75 0.19 106 M; solubility in the mix-
ture water and methanol 70:30 v/v¼ 0.058 0.002 mg/
mL 9.0 0.3 105 M) was synthesized as previously
described (Dalpiaz et al., 2012). PLGA 50:50, Purasorb
PDLG 5004 (Mw 30 000 Da) was kindly gifted by Purac
Biochem (The Netherlands). Pluronic F-68 (polyethylene-
polypropylene glycols), 7 n-propylxanthine (7 n-PX) were
obtained from Sigma Aldrich (Milan, Italy). Methanol,
acetonitrile, ethyl acetate and water were high-performance
liquid chromatography (HPLC) grade from Merck
(Darmstadt, Germany). The reversed-phase column
(Hypersil BDS C-18 5U cartridge column, 150 mm 4.6 mm
i.d.) and the guard column (packed with Hypersil C-18
material) were obtained from Alltech Italia Srl BV (Milan,
Italy). All other reagents and solvents were of analytical grade
(Sigma-Aldrich).
UDCA–AZT-loaded NPs
NPs were prepared according to the nanoprecitation technique
and single emulsion/solvent evaporation method. The method
by Fessi et al. (1989) was employed for the preparation of NPs
by nanoprecipitation. Briefly, PLGA (100 mg) and UDCA–
AZT (2.5 or 6.0 mg) were accurately weighted and dissolved in
4 mL of acetone. The organic phase was added under magnetic
stirring to the aqueous phase (20 or 60 mL) containing 50 mg
of Pluronic F-68. Particle precipitation occurred immediately.
After 10 min, the organic solvent was removed under vacuum
at 30 C using a rotavapor (Mod. B-480, Büchi
Laboratortechnick, Flawil, Switzerand). Empty NPs were
prepared according to the procedure previously described,
omitting the presence of the prodrug. When purified, the
samples were recovered from suspension by gel-chromatog-
raphy (Sepharose CL4B) or vacuum ultrafiltration.
Gel filtration chromatography was carried out using a
Sepharose CL4B (Sigma Chemical) gel. The gel was filled
into a column, avoiding bubbles and cracks. The column had a
length of 50 cm, an inner diameter of 2 cm and contained
160 mL of gel. The NP samples were eluted using deionized
water at a flow rate adjusted to 1.5 mL/min. The appearance of
the NPs in the eluate was pointed out in 20 min using a
turbidimeter (model DRT 15-CE, HF Scientific Inc., Fort
Meyers, FL).
Figure 1. Chemical formula of AZT, UDCA and their prodrug UDCA–
AZT obtained by ester-conjugation.
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The vacuum ultrafiltration was performed by using a
polycarbonate holder (SM 16510; Sartorius, Gottingen,
Germany) equipped with a polypropylene filter (cutoff
0.2mm; Pall Corporation, Ann Arbor, MI).
All samples were freeze-dried for 24 h at 55 C at a
pressure of 102 Torr (Lyovac GT2; Leybold-Heraeus,
Hanau, Germany). The freeze-drying of the NPs ensured the
elimination of any residual of the acetone that eventually
remained in the particles.
The single emulsion/solvent evaporation method was
carried out by dissolving either the PLGA (125 mg) and
UDCA–AZT (2.5 mg) in 2 or 4 mL of dichloromethane. This
organic solution was dispersed during 1 min by sonication at
25 Watts (XL 2000 Microson, Misonix, NY) into 10 or 30 mL
of water containing 50 or 100 mg of Pluronic F-68. Then, the
emulsion was kept at room temperature under stirring at
3000 rpm until the complete evaporation of the dichloro-
methane (2 h). Empty NPs were prepared according to the
procedure previously described, omitting the presence of
the prodrug. When purified, the resulting NPs were recovered
by ultrafiltration, as described above. All samples were
freeze-dried for 24 h. Tables 1 and 2 report the preparation
conditions of the NPs.
Determination of Pluronic F68 residuals
The amount of Pluronic F68 associated with NPs was
determined by a colorimetric method based on the formation
of a colored complex between two hydroxyl groups of Pluronic
F68, Ba2þ and an iodine molecule (Childs, 1975). Briefly,
10 mg of lyophilized NPs were dissolved in 2 mL of
dichloromethane. Then, 10 mL of deionized water was added
and stirred until complete evaporation of the solvent (2 h).
After the centrifugation of the water phase at 3500 g for 10 min
(model 4235, A.L.C., Milan, Italy), 1 mL of a 5% w/v BaCl2
solution in HCl 0.1 M and 1 mL of a solution of I2/KI (0.05 M/
0.15 M) were added to 4 mL of supernatant. Finally, the
absorbance of the samples was measured spectophotometri-
cally at 540 nm (WPA lighwave, Cambridge, UK) after 15 min
incubation at room temperature. No absorption was observed
when only PLGA polymer was used under identical condition.
Particle size measurement and morphological analysis
The shape and morphology of the samples were analyzed
by scanning electron microscope (SEM) (XL-40 Philips,
Amsterdam, The Netherlands). When necessary, before the
analysis freeze-dried NPs were purified by vacuum ultrafil-
tration from Pluronic F-68 in order to avoid interference.
Few drops of the concentrated reconstituted NP suspension
were placed on an aluminum stub (TAAB Laboratories
Equipment, Ltd, Berks, UK) using a double side sticky tab
(TAAB Laboratories Equipment, Ltd) and, after drying,
vacuum-coated with gold–palladium in an argon atmosphere
for 60 s (Sputter Coater Emitech K550, Emitech LTD,
Ashford, Kent, UK).
The size of the NPs was measured by PCS using a
Zetasizer Nano ZS (Malvern, Worcs, UK). Each freeze-dried
sample was diluted in deionized water until the appropriate
concentration of particles was achieved to avoid multi-
scattering events. The obtained homogeneous suspension
was examined to determine the volume mean diameter and
the polydispersity and repeated three times for each sample.
The data are the results of three independent experiments.
A colloid/particle fractionator SdFFF system (Model S101,
Postnova Analytics, Landsberg, Germany) described in detail



















NP1 UN1P – 50 20 527 143 0.525 24.7 – 0.9 0.3
Purified by ultrafiltration LO1P 2.5 50 20 1214 560 0.792 22.2 0.79 0.05 0.8 0.2
NP2 UN1 – 50 60 712 210 0.606 26.4 33.0 1.2
Unpurified LO1 2.5 50 60 576 120 0.389 27.3 0.78 0.04 34.5 2.2
NP3 UN1 – – 60 704 312 0.553 28.1 – –
Unpurified LO1 2.5 – 60 791 69 0.638 22.2 0.051 –
NP2
Unpurified LO2 6.0 50 60 597 172 0.573 13.6 1.53 0.07 33.0 1.1
NP2
Purified by gel filtration LO2P 6.0 50 60 753 150 (0.627) 28.4 0.84 0.04 0.5 0.2
In each sample, 100 mg of PLGA dissolved in 4 mL of organic phase (acetone) was employed. Loading and particle size data are reported as the
mean SD of three independent experiments.





















EM1 UN1P – 100 10 1 412 89 0.243 16.9 – 0.8 0.2
Purified LO1P 2.5 100 10 1 1201 470 0.760 18.7 0.83 0.06 0.9 0.3
EM2 UN1 – 50 30 2 850 149 0.592 13.2 – 28.5 1.3
Unpurified LO1 2.5 50 30 2 447 30 0.479 19.3 0.80 0.05 27.3 1.6
In each sample 125 mg of PLGA dissolved in diclorometane was employed. Loading and particle size data are reported as the mean SD of three
independent experiments.
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elsewhere (Contado & Argazzi, 2009, 2011), was also
employed to determine the size distribution of the particles.
Sample suspensions (0.1% w/v) were injected through a 50 mL
Rheodyne loop valve. An HPLC Pump PN1121 (Postnova
Analytics, Germany) was used to deliver the carrier. The outlet
tube from the channel was connected to a UV/Vis detector
Spectra SERIES UV100 (Thermo Separation Products)
operating at a fixed wavelength of 254 nm. The SdFFF
instrument was controlled by SPIN 1409 which was also
used to acquire the fractrograms; the registered data were
processed by FFF ANALYSIS; both were Windows compatible
programs provided by Postnova Analytics (Germany) together
with the instrument. The mobile phase was a 0.01% (w/v)
solution of Triton X-100 in Milli-Q water (Millipore S.p.A.,
Vimodrone, Milan, Italy), flowing at 2 mL/min. The fracto-
grams, i.e. the graphical results, were converted in particle size
distribution (PSD) assuming a particle bulk density of 1.3 g/mL
for all formulations.
HPLC analysis
The quantification of the prodrug UDCAAZT and its
potential hydrolysis product AZT was performed by HPLC.
The chromatographic apparatus consisted of a modular
system (model LC-10 AD VD pump and model SPD-10A
VP variable wavelength UVVis detector; Shimadzu,
Kyoto, Japan) and an injection valve with 20 mL sample
loop (model 7725; Rheodyne, IDEX, Torrance, CA).
Separation was performed at room temperature on a reverse
phase column Hypersil BDS C-18, 5U, equipped with a
guard column packed with the same Hypersil material. Data
acquisition and processing were accomplished with a
personal computer using Class-VP software (Shimadzu).
The detector was set at 260 nm. The mobile phase consisted
of a mixture of water and methanol regulated for the
analysis of both AZT and UDCA–AZT by a gradient profile
programed as follows: 10 min isocratic elution at H2O/
MeOH ratio 80:20 (v/v); 1 min linear gradient elution from
the water/MeOH ratio 80:20 (v/v) to 25:75 (v/v); 10 min
isocratically at the H2O/MeOH ratio 25:75 (v/v); after each
cycle the column was conditioned back to the initial
conditions for 10 min. The flow rate was 1 mL/min. The
xanthine derivative 7-n-PX was employed as internal
standard for human rat liver homogenates (see below). The
retention times for 7-n-PX, AZT and the prodrug
UDCAAZT were 6.5, 8.4 and 19.6 min, respectively.
For the analysis of UDCA–AZT alone the elution was
isocratic with a mixture H2O/MeOH 20:80 (v/v). In this case
the retention time of UDCA–AZT was 4.8 min.
The chromatographic precision for each compound was
evaluated by repeated analysis (n¼ 6) of the same sample
(25mM). The calibration curves of peak areas versus concen-
trationweregenerated in the range0.5–50mMforAZTdissolved
in aqueous phase and UDCAAZT dissolved in methanol or a
mixture of aqueous phase and methanol (70:30 v/v ratio).
UDCA–AZT content in the NPs
The NPs (1 mg) were accurately weighed using a high-
precision analytical balance (d¼ 0.01 mg; Model CP 225D;
Sartorius), and dissolved into 1 mL of dichloromethane. The
samples were reduced to dryness under a nitrogen stream,
then 1 mL of methanol was added and, after centrifugation at
12 000 g for 10 min, 10 mL were injected into the HPLC
system. All the values were obtained as the mean of three
independent incubation experiments. Preliminary experiments
indicated the absence of interferences by the components of
PLGA NPs on the chromatograms. The actual drug loading
(%, w/w) was calculated from the weight of the NPs and the
amount of drug incorporated.
In vitro UDCA–AZT release studies from NPs
An accurately weighted amount of NPs (15 mg of samples
NP1-LO1P, NP2- LO1, NP2-LO2P, EM1-LO1P and EM2-
LO1 or 7.5 mg of the sample NP2-LO2, all containing
0.12 mg of the prodrug UDCA–AZT) was added to 15 mL
of a mixture of water and methanol (70:30 v/v) and
immediately dispersed by sonication (30 s, at 25 W; XL
2000 Microson, Misonix, Farmingdale, NY). The samples
were maintained at 37 C and stirred mechanically (100 rpm)
during the release experiments. Aliquots (250mL) were
withdrawn at fixed time intervals and filtered upon centrifu-
gation at 13 000 g for 12 min using Microcon filter devices
(YM 30; Millipore Corporation, Bedford, MA). The with-
drawn volume was immediately substituted with same amount
of the mixture of water and methanol (70:30 v/v). The filtered
solution (10 mL) was injected into the HPLC apparatus for the
evaluation of UDCA–AZT contents. Preliminary experiments
indicated that concentrations of UDCA–AZT in the mixture
of water and methanol (70:30 v/v) were not significantly
altered by the microcon filtration process.
The dissolution studies of the prodrug were performed by
adding 0.15 mg of UDCA–AZT to 15 mg of the mixture of
water and methanol (70:30 v/v). Aliquots (150 mL) were
withdrawn at fixed time intervals and 10 ml of filtered samples
(0.45 mm) were injected into the HPLC system for UDCA–
AZT detection. The dissolution experiments were performed
in the absence and in the presence of 0.5% Pluronic-F68 in the
mixture of water and methanol (70:30 v/v). All the values
obtained are the mean of three independent experiments.
Preparation of rat liver homogenates
The livers of male Wistar rats were immediately isolated after
their decapitation, washed with ice-cold saline solution and
homogenized in 4 volumes (w/v) of Tris–HCl (50 mM, pH
7.4, 4 C) with the employment of a PotterElvehjem
apparatus. The supernatant obtained after centrifugation
(2000 g for 10 min at 4 C) was decanted off and stored at
80 C before its employment for kinetic studies. The total
protein concentration in the tissue homogenate was deter-
mined using the Lowry procedure (Lowry et al., 1951) and
resulted in 29.4 1.1 mg protein per microliter.
Kinetic analysis of UDCA–AZT in rat liver
homogenates
The prodrug UDCAAZT or its potential hydrolysis product
AZT were incubated at 37 C in 3 mL of rat liver homogen-
ates, resulting in a final concentration of 30 mM obtained by
adding 3 mL of 102 M stock solution in DMSO for each
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milliliter incubated. During the experiment, the samples were
shaken continuously and gently in an oscillating water bath.
At regular time intervals, 100mL of samples were withdrawn
and immediately quenched in 200 mL of ethanol (4 C);
100mL of internal standard (30 mM 7-n-PX) was then added.
After centrifugation at 13 000 g for 10 min, 300 mL aliquots
were reduced to dryness under a nitrogen stream, then 150 mL
of the water and methanol mixture (70:30 v/v) was added and,
after centrifugation for 10 min at 12 000 g, 10 mL was injected
into the HPLC system. The same procedure was adopted
in the presence of unloaded NPs (Sample NP2-UN1,
1.66 mg/mL), with the only difference that 50 mL of
dichloromethane was added to the withdrawn samples
before the extraction procedure. All the values were obtained
as the mean of three independent incubation experiments. A
preliminary analysis performed on blank rat liver homogenate
samples showed that its components did not interfere with the
AZT, UDCA–AZT and 7-n-PX retention times.
The accuracy of the analytical method was determined by
recovery experiments, comparing the peak areas of extracted
rat liver homogenate samples at 4 C (n¼ 6) with those
obtained by injection of an equivalent concentration of the
analytes dissolved in their mobile phase. For all compounds
analyzed, the calibration curves were constructed by employ-
ing eight different concentrations in rat liver homogenates at
4 C ranging from 0.5 to 50 mM and expressed as peak area
ratios of the compounds and the internal standard versus
concentration.
For stability studies of the nanoencapsulated UDCA–AZT,
3 mL of rat liver homogenate was spiked at 37 C with loaded
NPs (samples NP2-LO1, NP2-LO2, NP2-LO2P) resulting in a
final concentration of about 30 mM for encapsulated UDCA–
AZT. At 30 min of incubation, 1 mL of dichloromethane was
added and 250mL of samples were withdrawn and quenched
in 400 mL of ice-cold ethanol added with 200 ml of 30 mM
7-n-PX as internal standard. After 10 min of centrifugation at
13 000 g, 600 mL aliquots were reduced to dryness under a
nitrogen stream. About 300 mL of the water and methanol
mixture (70:30 v/v) was added and, after centrifugation,
10 mL was injected into the HPLC system. The accuracy of
the method was determined as described above. All the values
obtained are the mean of four independent experiments.
Results and discussion
Characterization of the NPs: size, z potential and
morphology
The formulation parameters and results of the physical–
chemical characterization of the particles obtained by
nanoprecipitation are reported in Table 1. The batch NP1 is
the only one subjected to the purification by vacuum filtration
before freeze-drying; the NP2 and NP3 batches were obtained
by increasing the volume of the aqueous phase (NP2) and by
omitting the surfactant (NP3) with respect to the formulation
conditions adopted for batch NP1. The sample NP2-LO2P
was purified by gel filtration.
The analysis showed that all the samples had a negative
z potential value, according to the polymer features,
characterized by the presence of carboxylic groups deproto-
nated at our experimental conditions. The z potential values
of the NPs obtained by nanoprecipitation ranged between 20
and 30 mV, except that in the not purified sample NP2-LO2
(z potential¼13.6 mV), obtained with a higher amount of
prodrug.
The presence of Pluronic F68 did not seem to influence the
z potential of NPs as no significant changes were observed
between the purified and unpurified samples.
In general, the nanoparticulate systems allow obtaining
relatively stable suspensions when their z potential is higher
than 30 mV as absolute value (Hunter, 1989). The samples
reported in Table 1 do not seem to reach this condition and the
analysis of their size by PCS appears to confirm this aspect.
Indeed, the size values indicate that the samples are
characterized by entities with a mean diameter between 500
and 800 nm if we exclude the sample NP1-LO1. These values
seem to represent samples highly polydispersed, i.e. the
powders which could contain particles of different sizes or
more, probably aggregates. The highest degree of aggregation
was observed in the case of batch NP1-LO1, likely due to the
combined effect of the prodrug dispersed in a relatively small
amount of water. In fact, in all other cases the aggregation was
more circumscribed. A possible reason is connected with the
increase of the aqueous phase, which favors the prodrug
dissolution by reducing its precipitation and its ability to act
as a nucleus of aggregation for NPs.
The presence of the surfactant coating the unpurified
samples did not seem relevant in reducing the aggregation of
the NPs. Indeed, the purified and unpurified samples of batch
NP2 and the batch NP3, prepared under the same conditions
than NP2 but in the absence of Pluronic, showed similar
aggregation degrees.
A different approach to size the NPs is offered by the
SdFFF, a separation technique able to sort micro- and
nanoparticles according to their effective mass. This
method detects the particles through UV measurements
(absorption and/or scattering) only after their separation, on
the contrary of batch measurements given by the PCS
technique. The complementarities of the two measurement
methods might be well understood by observing Figure 2,
where the PSD plots of some selected samples are reported.
The separation conditions were selected in order to
highlight only the sizes comprehended between 200 and
2000 nm, neglecting on purpose larger dimensions. Samples
NP1-UN1P and NP1-LO1P are classified by the PCS as
very polydispersed (PDI values 0.5 and 0.8, respectively)
with average sizes of 527 and 1214 nm (Table 1); the
SdFFF PSD plot (A) show that the NP1-UN1 contains
aggregates of roughly 650 nm, forming a single population
spanning between 300 nm and up to 1 mm, whereas the
NP1-LO1 contains either aggregates of sizes ranging from
250 to 800 nm, but also agglomerates of larger dimensions
which are not fractionated under the selected experimental
conditions but which exit immediately from the channel
and that appear in the PSD plot in the region of the small
sizes (5250 nm). The SdFFF measurements confirm there-
fore that the prodrug encapsulation in this formulation
promotes the particle aggregation.
On the contrary, the encapsulation of the prodrug on the
formulations of batch NP2 does not determine significant
changes in the PSD plots of the samples as highlighted by
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the plot B, where the two representative sample profiles
(UN1 – black and LO1 – gray) appear perfectly super-
posable, with a main peak centered at about 240–260 nm.
The similar behavior could be insight also by the similar z
potential values (26–27 mV). The secondary populations at
600 nm and 900 nm are of minor intensity and negligible
compared to the main one. The PCS measurements ascribe
to these samples instead, a certain polydispersity (PDI
Figure 2. Particle mass distributions of the samples. (A) NP1-UN1P and NP1-LO1P; (B) NP2-UN2 and NP2-LO2 and (C) EM1-UN1P and EM1-
LO1P. The conversion from the fractograms was achieved by setting a particle density of 1.3 g/mL for all samples. The fractionations were obtained
under programed field conditions by using a 0.01% w/v solution of Triton X-100 as mobile phase, flowing at 2 mL/min.
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values 0.6 or 0.4) and sizes around 710 nm for the UN1
sample and 580 nm for the LO1 sample. Therefore, the
SdFFF results indicate that the polydispersity values
obtained by PCS are mainly due to different degrees of
aggregation, occurring among particles of about 240 nm.
This phenomenon seems to be favored in a restricted
volume, such as a couvette, whereas it is hampered by the
spatial separation in the SdFFF channel.
Table 2 reports the characteristics of the particles obtained
by the emulsion/solvent evaporation method. In general,
z potential values of the unloaded NPs obtained by emulsion/
solvent evaporation method appear lower than those of
particles obtained by nanoprecipitation, probably due to a
different rearrangement of the polymer in this type of
preparation. The presence of the prodrug in the EM1 batch
provoked a relatively high aggregation of the NPs, as
observed previously also in the case of batch NP1.
The effect of aggregation in the presence of drug disappeared
as the external aqueous phase was increased probably owing
to enhancement of the prodrug dissolution.
The PSDs of the EM1 samples (Figure 2, plot C), chosen
as example for the emulsion formulation method, confirm the
presence of a single population of about 400 nm for the
sample EM1-UN1 and the aggregation of the particles when
the prodrug is present (EM1-LO1).
Figure 3 reports, as representative, the SEM microphotog-
raphy related to samples NP1-LO1P, NP2LO2P and
EM1-UN1P. These images evidence quite spherical and
well-formed NPs characterized by a significant polydispersity
mainly due to aggregation phenomena. These morphological
characteristics are in good agreement with the size data
obtained by PCS and SdFFF techniques.
Characterization of the NPs: UDCA–AZT loading
The polymer PLGA employed for the formulation of the NPs
was chosen with a molecular weight (30 kDa) suitable for
the encapsulation of drugs with relatively low molecular
weight (Dalpiaz et al., 2009). In the aim to verify the loading
effects, the different formulations proposed here keep con-
stant the type of polymer (PLGA) and surfactant (Pluronic
F68) and differ for the weight ratios between prodrug,
Pluronic F-68 and PLGA or for the different volumes of
organic and aqueous solvents which were used, as reported in
Tables 1 and 2. The actual UDCA–AZT loading (percent
w/w) were also reported in Tables 1 and 2 for the NPs
obtained by nanoprecipitation and emulsification techniques,
respectively. The loading values have been obtained by HPLC
analysis with isocratic elution at H2O/MeOH ratio 20:80
(v/v), as previously described (Dalpiaz et al., 2012). The
Figure 3. SEM micrographs of the samples NP1 -LO1P (A), NP2-LO2P (B), obtained by nanoprecipitation and EM 1-UN1 (C), obtained by emulsion–
solvent evaporation method.
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chromatographic precision for UDCAAZT dissolved in
MeOH or in a H2O/MeOH mixture 70:30 (v/v) was
represented by relative standard deviation (RSD) values
ranging between 0.95% and 0.96%. The calibration curves
of the prodrug were linear over the range of 0.5–50mM (n¼ 8,
r40.998, p50.0001). The employment of methanol as
co-solvent was necessary to increase the low solubility of
the prodrug in water. In particular, the solubility value of
UDCAAZT in water was 0.0030 0.0001 mg/mL
(4.75 0.19 106 M), whereas in the mixture of water and
methanol (70:30 v/v), it was 0.058 0.002 mg/mL
(9.0 0.3 105 M) (Dalpiaz et al., 2012). For this reason,
also the release studies of UDCA–AZT from the NPs were
performed in the same water/methanol mixture (see below).
The data showed in the Tables indicate that the prodrug
content in the nanoparticulate powders obtained by nanopre-
cipitation or by emulsion/solvent evaporation was not
modified by the vacuum-ultrafiltration purification process.
This is a very important data that shows how the process of
purification in the case of a very slightly water soluble drug as
the prodrug UDCA–AZT does not modify the drug loading,
but changes only the amount of surfactant present in the final
product. Indeed, as reported in Tables 1 and 2, the Pluronic
residual was dependent on the purification methods applied.
The unpurified particles showed a Pluronic residual of 33%
w/w, while the purified particles showed a residual of 0.5% or
0.9% w/w for vacuum ultrafiltration and gel filtration,
respectively. Therefore, the elimination of the Pluronic was
poorly affected by the method of purification, as demon-
strated in a previous work (Leo, 2006a). On the other hand,
the sample NP2-LO2P, purified by gel filtration, showed a
reduced prodrug content with respect to its parent unpurified
sample NP2-LO2. In this case the purification process, able to
perform a separation of solid particles on the basis of their
size, appeared able to separate the solid particles of the
prodrug not solubilized and adsorbed on the surface of the NP.
The absence of surfactant during the preparation appeared
detrimental for the UDCA–AZT loading as evident from the
batch NP3 in which only traces of prodrug were found
(0.051% w/w), notwithstanding the sample was unpurified.
The lack of drug loading in this batch is probably due to its
high drug lipophilicity that, in the absence of Pluronic,
determines the complete drug adhesion on the walls of the
glassware and the absolute lack of drug recovery. On the other
hand, in the presence of surfactant, drug loading was of about
0.8% w/w both in the samples unpurified and purified,
irrespective of the amount of aqueous phase used in the
preparation (NP1 and NP2 batches). Increasing the theoretical
content of the drug (NP2-LO2) an increase of its actual
loading was observed (until 1.53% w/w) without current
increase of the particles’ size. After gel filtration, the prodrug
content appeared slightly 40.80% being eliminated the most
part of unloaded drug.
The samples obtained by simple emulsion/solvent evap-
oration method (Table 2) showed prodrug contents around
0.8% w/w. The formulation conditions for the sample EM1
(high Pluronic F-68 amounts and small water phase
volumes) appeared to improve the prodrug presence in the
nanoparticulate powder. Indeed the prodrug percentage
found for the sample EM1-LO1 was the same as detected
for the sample EM2-LO1, that was not purified and was
prepared using different organic/water phase ratio and a
lower Pluronic F68 amount. Therefore, these parameters
seem to not influence the recovery of the prodrug in
nanoparticulate powder.
In vitro N6-cyclopentyladenosine release studies
from NPs
The release studies of the prodrug from the loaded
nanoparticulate samples have been performed in a mixture
of water/methanol 70:30 (v/v) with the aim to induce the
solubility of UDCA–AZT in water, which is very poor
(0.0030 0.0001 mg/mL – 4.75 0.19  106 M). Therefore,
in order to create sink conditions, the release studies were
performed in the presence of 30% methanol in the release
medium, with the aim of optimizing both the prodrug
solubility and HPLC detection for the release studies. Even
if these conditions do not mimic the physiological conditions,
we considered our release studies as a way of comparison of
the ability of the NPs to control the release of the prodrug.
Figure 4 reports the release profiles of UDCA–AZT from the
loaded NPs. The release patterns are compared with those of
the dissolution during time of the raw powder of the prodrug
in the water/methanol mixture 70:30 (v/v), both in the
absence and in presence of 0.5% Pluronic F-68. Also in this
case, the amounts of prodrug to be solubilized were chosen in
manner to obtain, after complete dissolution, a concentration
of prodrug corresponding to the 15% of its saturation value.
It can be observed that the dissolution rate of UDCA–AZT
in the absence of surfactant appeared very low. Indeed, after
eight hours of incubation, 530% of the total raw powder
amount was solubilized. On the other hand, the presence of
the surfactant in the incubation medium allows to obtain a
complete dissolution of the prodrug within 1.5 h. The
presence of the surfactant seems, therefore, to play an
important role in reducing the interfacial tension between
the solid prodrug and the liquid phase, allowing a complete
wetting of the raw powder of the prodrug. It is interesting to
observe in Figure 4(A) that the sample NP1-LO1P showed a
release pattern characterized by a high-burst effect (480%),
followed by a release of the prodrug that was completed
within one hour. On the whole, the release rate of UDCA–
AZT from all samples appeared higher than the dissolution
rate of the prodrug in the presence of Pluronic F-68. This
phenomenon has been attributed to the size of the particles in
the mm or nm ranges, that seemed to induce a great increase
of surface contact of the solid prodrug with the incubation
medium, allowing therefore to increase the dissolution rate
with respect to the raw powder. However, as NP1-LO1P
sample is larger than the others with a low drug loading, we
would expect a slower drug diffusion rate. The relatively fast
release of UDCA–AZT from sample NP1-LO1P suggests that
the prodrug amount encapsulated in the interior structure of
the NPs is very poor. As a consequence, the formulation
conditions chosen for sample NP1-LO1P, appear detrimental
for an efficient encapsulation of the prodrug in the NPs. The
low amount of organic phase employed during formulation
seems useful to induce adsorption phenomena of UDCA–
AZT to the NPs, but not their loading. On the other hand, the
formulation conditions employed for sample NP2-LO1
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optimized the prodrug encapsulation in the PLGA NP. Indeed,
following a burst effect of 60%, probably due to the
presence of the prodrug adsorbed on the surface of NP that
has not been removed by purification, the release of UDCA–
AZT appeared completed within six hours, with a release rate
significantly lower than the dissolution rate of the prodrug in
the presence of surfactant. It is important to remark that,
despite the sample NP2-LO1 has a smaller size and has not
been purified, its burst effect appeared the lowest among the
burst effect values of the samples reported in Figure 4(A).
This finding can be explained assuming that the formulation
parameters allow to obtain a low porous and high compact
matrix which leaded to a reduction in the drug dissolution rate
despite the reduction of the particle size. As a consequence,
the enhancement of the volume of the water phase with
respect to the formulation conditions chosen for the sample
NP1-LO1, appears to have favored the encapsulation of the
prodrug in the NP2-LO1 NPs, probably by increasing the
efficacy of the nanoprecipitation of the polymer when it was
desolvated from acetone by action of the aqueous ‘‘non-
solvent’’. Finally, keeping constant the formulation conditions
of the samples NP2 and increasing the initial amount of drug
(theoretical loading), we obtained NPs characterized by a
lower ability to control the release of UDCA–AZT. Indeed,
the samples NP2-LO2 and NP2-LO2P showed burst effects
values about the 74% and 60%, respectively, then the prodrug
release was completed within six hours, but with a rate in the
first phases higher than that showed by the sample NP2-LO1.
The increase of the initial prodrug amount seems therefore
to have induced the creation of a porous structure in the
polymeric matrix of the NPs, with a consequent increase of
the release rate of UDCA–AZT. Considering the samples
NP2-LO2 and NP2-LO2P, we can notice how the presence
of Pluronic does not substantially modify the kinetics of drug
release from NPs nor the extent of the burst effect which is
instead only influenced by the preparation parameters
adopted.
Figure 4(B) reports the release profiles of UDCA–AZT
from the NPs obtained by simple emulsion/solvent evapor-
ation. Both the samples showed a poor ability to control the
release of the prodrug, with a burst effect of about 75%; the
90% of UDCA–AZT was released within one hour and the
release was completed within three or four hours. As a
consequence, the formulation conditions chosen for EM1 and
EM2 batches appear inappropriate for the encapsulation of the
prodrug in the PLGA NPs. Moreover, the inability to control
the release of the prodrug was showed by other samples,
obtained at the same conditions of the samples EM1-LO1P
and EM2-LO1, but by increasing the prodrug amounts during
preparation (6.0 mg). In particular, despite a significant
increase of loading, the prodrug release was characterized
by burst effects ranging from 85% to 90%, with a complete
release of the drug within two hours. It is probable that
UDCA–AZT is able to reach the aqueous phase where
Figure 4. In vitro release of UDCA–AZT from PLGA NP, obtained by nanoprecipitation (A) or emulsion/solvent evaporation (B) methods. The release
profiles are compared with those of the raw UDCA–AZT powder dissolution during time in the absence or in the presence of 0.5% Pluronic F-68.
Results are the means of three independent experiments.
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Pluronic F-68 is dissolved, during the solidification phase of
polymer. Only a rapid solidification phenomenon, such as that
allowed by nanoprecipitation seems to consent the UDCA–
AZT encapsulation in the PLGA NP. We have previously
verified that a moderately water-soluble drug, the N6-
cyclopentyladenosine (CPA), can easily diffuse in aqueous
phase during the preparation of PLGA NPs, both by
nanoprecipitation and single or double emulsion/solvent
evaporation methods. Using such methods, either a poor
grade of CPA encapsulation or an unsatisfied control of its
release was achieved (Leo et al., 2006b). We have therefore
demonstrated that the lipophilic prodrug 50-octanoyl-CPA
(Dalpiaz et al., 2001) can be encapsulated in PLA NP and be
able to control its release. These satisfactory results were
obtained by the nanoprecipitation technique (Dalpiaz et al.,
2005; Leo et al., 2006a). It is important to remark that CPA is
an adenosine derivative, whereas AZT is a timidine deriva-
tive. Both these derivatives are moderately water-soluble and
an increase of their lipophilicity by a prodrug synthesis allows
to obtain their encapsulation in polymeric NPs, with results
optimized by the nanoprecipitation procedure.
Hydrolysis studies of free and encapsulated
UDCAAZT in rat liver homogenates
On the basis of the encapsulation and release results, the
samples NP2-LO1, NP2-LO2 and NP2-LO2P appear poten-
tially useful for the targeting of the prodrug UDCA–AZT in
specific sites of the body where the antiviral activity of
zidovudine is required. In particular, the unpurified and
Pluronic coated samples NP2-LO1 and NP2-LO2 appear
potentially suitable for the prodrug targeting in the CNS.
Indeed, it has been demonstrated that PLGA NPs coated with
Pluronic F-68 can induce drug delivery in the brain (Gelperin
et al., 2010). The AZT targeting in CNS should be of great
importance because HIV is able to easily reach the brain
where it induces neurological disorders ranging from mild
cognitive impairments to the severe AIDS dementia complex
(Davis et al., 1992; Gray et al., 1996). Even if anti-HIV agents
can be efficacious in periphery, they are in general unable to
reach the CNS and that therefore becomes a sanctuary of the
virus from which the periphery can be continuously reinfected
(Kolson & Gonzales Sacrano, 2000). Moreover, the purified
sample NP2-LO2P appears potentially useful for the prodrug
targeting in the macrophages, that when infected by HIV
produces and harbor the virus for a long period (Carter &
Ehrlich, 2008). As a consequence, the opsonization and the
following phagocytosis of the purified NPs by the macro-
phages of the mononuclear phagocytic system (MPS) (Owens
III & Peppas, 2006) can constitute an efficacious way to target
UDCA–AZT in an important therapeutic site of AZT.
In the aim to evaluate the ability of the NPs to protect and
stabilize the prodrug in physiologic environments, we have
compared the hydrolysis rate of UDCA–AZT in rat liver
homogenates in the free and encapsulated forms. We have
chosen the rat liver homogenates because the hydrolysis rate
of the prodrug is relatively fast (Dalpiaz et al., 2012). The
average recoverySD of UDCA–AZT and AZT from rat
liver homogenates were 83.2 2.9% and 85.5% 3.4%,
respectively. The concentrations of these compounds were
therefore referred to as peak area ratio with respect to their
internal standard 7-n-PX. The precision of the method based
on peak area ratio was represented by RSD values ranging
between 1.1% and 1.3%. The calibration curves referred to
AZT and its prodrug UDCA–AZT incubated in rat liver
homogenates were linear over the range 0.5–50mM (n¼ 8,
r40.989, p50.0001).
As reported in Figure 5, UDCA–AZT was degraded in rat
liver homogenates, following a first order kinetic with a half-
life of 2.78 0.15 min. This value appears in good agreement
with that obtained by previous studies on UDCA–AZT
pharmacokinetics in same incubation media, where it was
demonstrated that the prodrug was hydrolyzed allowing the
release of AZT (Dalpiaz et al., 2012). This process was
completed within 30 min, suggesting the need to increase the
half-life value of UDCA–AZT in the case of potential in vivo
administration. The stability studies have been performed first
by evaluating the effect of the presence of the unloaded NPs
on the hydrolysis of UDCA–AZT by rat liver homogenates.
As reported in Figure 5, the degradation curve of UDCA–
AZT appears superimposable with that of its degradation in
the presence of the sample, i.e. the unloaded and unpurified
NPs of the batch NP2. In particular, the half-life of UDCA–
AZT in the presence of the unloaded NPs was 2.50 0.15.
This value was not significantly different from the half-life
value of UDCA–AZT alone indicating that the presence of the
coating of Pluronic on NPs does not change the half-life value
of the prodrug. These data are in good agreement with those
obtained by previous pharmacokinetic studies of different
drugs and prodrugs in the presence of unloaded PLA, PLGA
or solid lipid micro and NPs (Dalpiaz et al., 2001, 2002, 2005,
2008, 2009, 2010; Leo et al., 2006a,b). The amounts of AZT
and UDCA–AZT detected after 30 min of incubation of the
free or encapsulated prodrug in rat liver homogenates are
reported in Figure 6. All the values are reported as the
percentage of the overall amount of incubated prodrug. It can
be observed that after this time period the free prodrug
appeared totally hydrolyzed, with the 100% of AZT released
and the total absence of UDCA–AZT. On the other hand, the
incubation of the sample NP2-LO1 allowed saving more than
50% of the UDCA–AZT incubated for 30 min in rat liver
Figure 5. Degradation profiles of the free prodrug UDCAAZT in rat
liver homogenates in the absence or in the presence of unloaded
nanoparticulate systems obtained by nanoprecipitation. All the values are
reported as the percentage of the overall amount of incubated prodrug.
Data are reported as the mean SD of four independent experiments.
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homogenates. Indeed, lower amounts of UDCA–AZT were
hydrolyzed with respect to the free prodrug, as confirmed by
the release of the 48% of AZT. The samples NP2-LO2 and
NP2-LO2P have also contributed to save the prodrug from a
complete hydrolysis, even if their efficacy appeared lower
with respect to the sample NP2-LO1. In this case the
amounts of UDCA–AZT saved ranged between 24% and
30% with corresponding release of AZT ranging from 69%
to 76%. These results indicate that the ability of the PLGA
NP to stabilize the prodrug in rat liver homogenates is
greatly related to their ability to control the release of
encapsulated UDCA–AZT. Interestingly, poor differences
were found between the samples NP2-LO2 and NP2-LO2P,
confirming that the presence of Pluronic F-68 on the surface
of the NPs do not alter the hydrolysis rate of the
encapsulated prodrug.
Conclusions
We have demonstrated that PLGA NPs obtained by
nanoprecipitation in the presence of Pluronic-F68 as surfac-
tant, are able to encapsulate and control the release of a
prodrug of zidovudine (AZT), obtained by its conjugation
with UDCA. The encapsulated prodrug UDCA–AZT shows
in physiologic fluids, an increased stability with respect to
the free form. Despite these interesting aspects, the loading
of the formulations appeared relatively low, whereas the
PDI, burst and release values were relatively high.
Therefore, this type of device can be considered useful for
in vitro study about opsonization and the following phago-
cytosis by macrophages. The ability of the described
nanoparticles to increase the dissolution rate of the prodrug,
with respect to its raw solid form, may allow to obtain an
appropriate delivery of the prodrug for studies that can
elucidate its effect in solubilized form in the macrophages,
where an anti-HIV action should be needed in the case of
AIDS syndrome.
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